Amarantus Bioscience Holdings Inc (AMBS)

[Solantey]

It's only a matter of time before AMBS is trading near Jason Napadano's target of .20.

Shorting AMBS at the current share price makes no sense.

1,000% upside over the next year versus 10% downside.

AMBS is the best opportunity in the market to earn substantial profits over the next 18 months and beyond.

"The next Amgen in its infancy."

Follow the company on Twitter: @AmarantusBio

p.s. I noticed there was a buy order on Level 2 on Friday for 1,000,000 shares@.043 and another one for 1,000,000 shares@.04.